BridgeBio Pharma Inc (BBIO)
23.42
+0.18
(+0.77%)
USD |
NASDAQ |
Nov 22, 13:25
BridgeBio Pharma Shareholders Equity (Quarterly): -1.230B for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -1.230B |
| June 30, 2024 | -1.093B |
| March 31, 2024 | -1.050B |
| December 31, 2023 | -1.354B |
| September 30, 2023 | -1.208B |
| June 30, 2023 | -1.362B |
| March 31, 2023 | -1.226B |
| December 31, 2022 | -1.255B |
| September 30, 2022 | -1.138B |
| June 30, 2022 | -1.026B |
| March 31, 2022 | -1.041B |
| December 31, 2021 | -870.41M |
| Date | Value |
|---|---|
| September 30, 2021 | -743.40M |
| June 30, 2021 | -464.29M |
| March 31, 2021 | -395.29M |
| December 31, 2020 | 57.91M |
| September 30, 2020 | 163.76M |
| June 30, 2020 | 265.76M |
| March 31, 2020 | 380.72M |
| December 31, 2019 | 408.45M |
| September 30, 2019 | 459.76M |
| June 30, 2019 | -316.12M |
| March 31, 2019 | 252.14M |
| December 31, 2018 | 314.88M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-1.362B
Minimum
Jun 2023
408.45M
Maximum
Dec 2019
-708.91M
Average
-1.033B
Median
Shareholders Equity (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 32.35M |
| Pfizer Inc | 92.29B |
| Vertex Pharmaceuticals Inc | 15.63B |
| PTC Therapeutics Inc | -1.054B |
| Bristol-Myers Squibb Co | 17.14B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 664.98M |
| Total Liabilities (Quarterly) | 1.883B |
| Debt to Equity Ratio | -1.398 |
| Current Ratio | 3.193 |
| Net Debt Paydown Yield | -0.00% |